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Abstract

The identification and quantification of proteins and enzymatic activity in living
tissues frequently requires the use of invasive procedures such as biopsy. These techniques
can inhibit measurements of protein levels in real-time, and the disruption of tissue can
lead to the loss of important information concerning the spatial distribution and differential
activities in various cell types. The use of small organic fluorescent probes that rely on
activation or accumulation within a tissue embody robust methods of detection that address
these issues. This dissertation describes the design, synthesis and evaluation of fluorescent
probes that can detect the enzyme thioredoxin reductase (TrxR).
TrxR enzymes in mammals are a group of selenoproteins that incorporate the
selenocysteine (Sec) residue on the active site. This gives TrxR greater reactivity and
broader substrate specificity compared to other oxidoreductase enzymes. The thioredoxin
system is overexpressed in most cancers, where it serves the function of providing reducing
equivalents responsible for promoting cell growth and division, whilst inhibiting apoptotic
factors.
In

this

study,

turn-on

probes

were

synthesized

by

conjugating

a

seminaphthorhodafluor to a quenching moiety that is selective for TrxR. Based on docking
simulations, the diselenide quencher had high affinity for the enzyme compared to the
disulfide analogues. Probe 1a was selective for TrxR against other biological reductive
species. It also had a fast turn-on response and higher fluorescence output in comparison

i

to other published disulde probes and also its disulfide analogue, 1b. 1a also had a low
IC50 value, which inspired the design of a new generation of theranostic probes.
A new series of probes (11, 12 and 13) was synthesized by conjugating
fluorophores to a selenadiazole ring. The Se-rings were envisioned to covalently bind to
the Sec residue of the TrxR active site, thus inhibiting the enzyme activity. Breaking the
Se-N bond of the selenadiazole changes the optical properties of the probe and a
fluorescence response should be observed. These probes had an absorption in the UV-Vis
region in buffer and showed no response with ROS and reductive species. In cells, there is
however absorption in the visible region (530 nm, 645 nm emission), which points to a
potential reaction of the probes. Low IC50 values were also obtained as predicted;
suggesting similar mechanism of action to other selenadiazole drugs that target TrxR.
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Chapter 1: Fluorogenic probes for thioredoxin reductase activity

Material from this chapter has been published: Tendai J. Mafireyi, Jorge O. Escobedo and
Robert M. Strongin*, Fluorogenic probes for thioredoxin reductase activity. Results in
Chemistry 2021, 3, 100127.
The published paper has been modified

Abstract
The thioredoxin system is vital in maintaining the cellular redox state and is
implicated in various cancers and other diseases. It comprises thioredoxin reductase,
thioredoxin and NADPH. Various methods have been developed for the detection and
quantification of the thioredoxin reductase enzyme. Most of these methods suffer from
poor specificity, hence there is need to develop more robust and specific techniques.
Recently, there has been an increased interest in fluorescent probes that can target
thioredoxin reductase. This review highlights the progress in the synthesis and application
of the different fluorescent probes that have been employed for this purpose.
Keywords: thioredoxin reductase, thioredoxin, selenocysteine, fluorescent probes, biosensors,
enzyme activity, cellular redox status, cancer detection
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Introduction
Structure of thioredoxin reductase enzymes
Thioredoxin reductase enzymes (EC 1.8.1.9) in mammals are a group of
selenoproteins that belong to a family of homodimeric pyridine-nucleotide oxidoreductases.
They control the cell redox state by functioning as reducing equivalents for many proteins
and cellular processes. These enzymes exist in three main isoforms; in the cytosol as TrxR1,
in mitochondria as TrxR2 and as a third form, thioredoxin-glutathione reductase (TGR)
which is mainly expressed in male germ cells.1 TrxR2 differs from TrxR1 in possessing an
N-terminal mitochondrial import sequence.2 TGR is unique in that it contains a C-terminal
thioredoxin reducing domain as well as an N-terminal gluathione reducing domain,
enabling it to connect the two main antioxidant pathways in organisms.3
Each monomer of TrxR (Figure 1.1) has a molecular weight of 55-60 kDa
depending on its cellular location, and includes an FAD prosthetic group and an NADPH
binding site, both of which are required for the enzyme’s catalytic process.4, 5 Another
member of the pyridine-nucleotide oxidoreductase family, glutathione reductase, has 64 %
sequence homology to TrxR, which includes a -Cys-Val-Asn-Val-Gly-Cys- redox-active
site.6 However, TrxR also has a second redox active site on the C-terminal that incorporates
the unique selenocysteine (Sec) residue (Figure 1.1), affording this enzyme significantly
greater catalytic efficiency and broader substrate specificity compared to other
oxidoreductase enzymes that utilize cysteine (Cys).6-9
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Figure 1.1. (top) A subunit of TrxR showing the A chain (cyan) and the B chain (green). Structures
were obtained from the protein data bank and visualized using UCSF Chimera 10, 11 (bottom) Sec,
the selenium analog of Cys, is a unique residue found on the TrxR active site.

Sec is the 21st amino acid and only differs from Cys by the replacement of selenium
in place of sulfur. The larger size and polarizability of selenium in comparison to sulfur
renders Sec a more nucleophilic amino acid. Sec has a pKa ~ 5.2, whereas Cys residues
typically have a pKa closer to ~ 8.5. Therefore, the selenol residue in mammalian TrxR is
efficiently deprotonated at physiological pH, leading to greater enzymatic efficiency.
Engineered TrxR, with Cys replacing the Sec residue, displays reduced catalytic efficiency
by ~ 2 orders of magnitude.
Insertion of Sec into the TrxR sequence during protein translation occurs through
the UGA codon, which is normally a stop codon. This recoding of UGA into a Sec codon
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occurs when the mRNA 3′ untranslated region known as the selenocysteine insertion
sequence (SECIS) is detected by the ribosome.12, 13

The thioredoxin reductase system and its mechanism of action
The thioredoxin reductase system is comprised of TrxR, NADPH and thioredoxin
(Trx). The mechanism of action has been shown to be quite complex and consists of many
steps, the first being the formation of the NADPH-FAD charge complex on one subunit of
the homodimeric enzyme. This involves a conformational change in which the NADPH

Figure 1.2. A. Electron transfer between NADPH and the FAD domain, leading to the reduction
of the disulfide (-S-S-) bond on one subunit of TrxR and the selenylsulfide (-Se-S-) bond on the
C-terminal of the second subunit. B. The thioredoxin reductase system catalytic mechanism for Trx
reduction.
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domain rotates so that it comes within proximity to FAD. The rotation also exposes the
active site of the enzyme for thioredoxin access. The flavin is then reduced to FADH 2,
followed by electron transfer to reduce the active site disulfide on the same subunit (Figure
1.2A). This part of the mechanism is similar to that of other oxidoreductase enzymes.
However, the nascent dithiol then reduces -Cys-Sec- on the C-terminal active site of the
second subunit of TrxR (Figure 1.2B). Sec becomes exposed on the surface of the enzyme
to reduce the disulfide (-Cys-Cys-) of Trx.1, 14
Trx, the major substrate for TrxR, is a protein disulfide oxidoreductase which can
reduce disulfides at a rate five orders of magnitude faster than dithiothreitol (DTT).15 In its
reduced form, Trx controls cellular redox potential and plays a protective role by
scavenging ROS-derived radicals.7,

16

As a reducing equivalent for other proteins, it

protects cells from tumor necrosis factor, anti-Fas antibody and ischemic reperfusion
injury.17, 18 Other known functions of Trx include inhibiting the pro-apoptotic protein,
ASK-1 and also PTEN, a tumor suppressor protein.19,

20

Besides its cytoprotective

properties, Trx also activates redox factor-1 (Ref-1) and promotes DNA repair through the
reduction of ribonucleotide reductase, amongst other proteins responsible for cell growth
and survival.
Overall, the thioredoxin system can promote growth and prevent apoptosis of
cancer cells.21 High levels of TrxR have been found in colorectal carcinomas, breast cancer,
prostate cancer and human lung carcinoma, at levels that are ~ ten-fold greater than in
normal tissues.22-25 In melanoma cells TrxR levels can correlate with metastases where it
aids growth and promotes DNA synthesis while inhibiting apoptosis-inducing proteins and
5

tumor suppressing proteins such as p53.22, 23, 26-31 One study showed that cancer cells
morphologically revert into normal cells when TrxR is knocked down via siRNA. This
finding points to the role of TrxR in cancer progression.31 Additional investigations have
also shown inhibited TrxR expression in Parkinson’s disease and stroke.32, 33

Non-fluorescent methods for detecting TrxR
The importance of TrxR in disease necessitates useful and practical methods for
monitoring this enzyme. A common commercial method is the DTNB assay which
employs Ellman’s reagent (5,5-dithio-bis-(2-nitrobenzoic acid)) for the colorimetric
quantification of TrxR in the presence of NADPH.34 DTNB is reduced to the yellow
colored TNB2-, and absorption shifts from 305 nm to 412 nm (Figure 1.3).
A modified version of this assay is the insulin end-point assay in which TrxR
reduces Trx which goes on to reduce the insulin disulfide bonds. The free insulin thiols
will then reduce DTNB2- to TNB2-. This is a type of an end-point or discontinuous assay
since it can be quenched by a chaotrope such as guanidium hydrochloride before
quantifying the free thiols. DTNB is however a substrate for other biological reducing
species, and in cell extracts, background activity can range from 15-40 %. In addition, the
assay can only be used in cells after they have been lysed.35
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Figure 1.3. Reduction of DTNB2- by a thiol to form TNB2- , a yellow compound that has λabs at
420 nm. Oxidoreductase enzymes, including TrxR, can also be quantified through a reaction with
DTNB.

The SC-TR assay is a method involving selenocystine (SC) reduction by TrxR that
is readily monitored via the consumption of NADPH (λabs 340 nm). This method not only
allows quantification of TrxR but gives the relative abundance of TrxR to Trx. It was
developed for use with spectrophotometry and is conducive for high throughput screening
in multi-well plates. The SC-TR assay is highly specific since selenocystine could not be
reduced by biothiols and other enzymes such as glutathione reductase. A limitation is the
use of UV-Vis absorption which is subject to interference from other biomolecules such as
NADPH, which absorbs in the same region.35 Immunological methods have been used to
monitor TrxR activity not only in melanoma cells but also in blood plasma. However, these
techniques are generally regarded to be not cost effective and prone to error and false
negatives.27, 28, 36
Fluorescent probes can have enhanced utility in the detection of TrxR due to their
sensitivity and capability to give high temporal and spatial resolution. In comparison to the
methods described to date, fluorescent probes are also a potential non-invasive way to
detect biological analytes.37, 38 Ideal fluorescent probes should be highly sensitive such that
7

they can be used in low concentrations, down to the nanomolar range. Fluorophores with
a high signal to background ratio are therefore of interest, with near-infrared fluorophores
being desirable.39 In this focused summary, we highlight fluorescent probes that have been
synthesized and used for the detection of thioredoxin reductase activity. Additional related
probes have also been used to target selenols and thioredoxin, but these will not be
covered.40-42

Probes for monitoring TrxR activity
The Fang group designed, synthesized, and evaluated TRFS-green, the first off-on
fluorescent probe selective for TrxR (Figure 1.4), which provides a convenient and direct
method to detect and assay the TrxR enzyme.43 It consists of a five-membered dithiolane
ring conjugated to a fluorescent naphthalimide via a carbamate linkage. TRFS-green has a
λem = 480 nm at λexc = 373 nm which shifts to λem = 538 nm at λexc = 438 nm when the
probe is reduced by TrxR in the presence of NADPH under physiological conditions. A 10
µM solution of TRFS-green in the presence of TrxR (75 nM) and NADPH (200 µM) leads
to a gradual increase in fluorescence over 180 min. The proposed turn-on mechanism for
TRFS-green was validated via HPLC monitoring.
When the disulfide bond is reduced, a nucleophilic thiolate is formed which
promotes intramolecular cyclization to give a five membered cyclic oxathiolanone and the
fluorescent naphthalimide. TRFS-green is selective against small reducing thiols and
structurally-related glutathione reductase and lipoamide dehydrogenase. Hep G2 cells and
cell lysates containing TrxR also show reduction of TRFS-green, but not in the presence
8

of 2,4-dinitrochlorobenzene (DNCB), a known inhibitor of TrxR. Despite the selectivity
of this probe, it still has relatively low binding efficiency with a Km of 189 µM, and the
fluorescence increase does not plateau after 3 h.43 The lengthy time for the signal to plateau
is due to the slow cyclization-driven step to uncage the fluorophore.44 TRFS-green has also
been used to image the TrxR activity in HeLa cells in different studies.45, 46
A red-shifted probe, TRFS-red (Figure 1.4), was synthesized by conjugating a Nile
blue fluorophore with the dithiolane quencher. TRFS-red has λmax,abs at 530 nm that is
shifted to 615 nm in the presence of TrxR and NADPH.47 When excited at 615 nm, the
reduced probe fluoresces at 661 nm and the increase in fluorescence plateaus in 120 min.
TRFS-red also has an improved 90-fold fluorescence increase compared to TRFS-green’s
~35-fold increase. This is a result of the positively charged iminium cation on TRFS-red
that enhances affinity between the probe and the negatively charged C-terminal of TrxR.
TRFS-red is also selectively reduced by isolated TrxR and by HeLa cells. The turnon response of 10 µM TRFS-red in cells is faster (1 h) in comparison to TRFS-green (4 h).
This probe predominantly localizes in the cytosol, showing higher selectivity for TrxR1.47
A third probe in the TRFS series, Mito-TRFS, was synthesized to selectively target
mitochondrial TrxR (TrxR2).33 Mitochondria are known to produce ROS which can cause
oxidative stress in disease. Since TrxR plays a major role in controlling ROS levels in cells,
its activity can be used to monitor disease states.

9

Figure 1.4. The TRFS series of probes synthesized by Fang and co-workers. Turn-on mechanisms
for TRFS-green and Fast-TRFS are also shown (adapted with permission from 43, 44, Copyright
2013, 2019, American Chemical Society).

Similar to TRFS-green, Mito-TRFS has a naphthalimide fluorophore conjugated to
the 1,2-dithiolan-4-ol moiety, as the TrxR recognizing motif. A triphenylphosphonium
group is present in Mito-TRFS for mitochondrial targeting. This probe has λmax,abs = 375
nm and emits at 480 nm. In the presence of TrxR, the disulfide bonds are reduced, uncaging
the fluorophore and the probe emits at 540 nm (λexc = 438 nm). The turn-on response of
Mito-TRFS is relatively rapid, with a 30-fold increase that plateaus in 1 h. As in the case
of TRFS-red, the improved kinetics is attributed to the positive charge on Mito-TRFS that
10

facilitates binding to the negatively charged enzyme active site while enhancing the
hydrophilic nature of the probe. Fluorescence colocalization experiments confirm MitoTRFS distribution in mitochondria. This is the first probe to directly detect TrxR2 activity
in living cells. The study also showed a decline in TrxR2 activity in Parkinson’s disease.33
Mito-TRFS was additionally employed in a separate study to image TrxR2 in HeLa cells.48

In a related study, the Fang group altered the linker units and TrxR recognition
moieties to evaluate properties enabling faster reaction times and heightened selectivity.44
They found that 6-membered ring dithianes are not responsive to the enzyme, in contrast
to 5-membered ring dithiolanes. This results from heightened ring strain and reactivity
associated with smaller rings. Cyclic diselenides, in contrast, are more inclined towards
reduction by GSH. Among all the synthesized probes, Fast-TRFS (Figure 1.4) stands out
due to its quick turn-on response. HPLC-MS data confirms the turn-on mechanism of FastTRFS being due to cleavage of the disulfide bond with no cyclization-driven release (CDR)
of the fluorophore. However, with prolonged incubation (240 min), there is a decrease in
the fluorescence due to re-oxidation of the thiols to the disulfide.

Fast-TRFS shows an 80-fold increase in fluorescence that peaks at ~ 5 min (λexc =
345 nm, λem = 460 nm). Other potential reducing/interfering agents such as Trx, glutathione
reductase, diaphorase, amidehydrolase, bovine serum albumin, GSH, NADPH, Cys and
Sec have minimal interference to TrxR. This probe displays a higher selectivity for TrxR
over GSH (50 fold) compared to TRFS-red (12.8) and TRFS-green (15.2).Treatment of
11

HeLa cell lysates with Fast-TRFS also gives a more rapid and intense (70-fold)
fluorescence increase in comparison to previously reported probes, enabling dosedependent visualization of TrxR. The researchers have used Fast-TRFS in a potential TrxR
assay technique and also in the identification of TrxR inhibitors which may be useful for
cancer treatment.44

The first two-photon fluorescent probe for TrxR, TP-TRFS (Figure 1.4), was
recently synthesized through the conjugation of 2-acetyl-6-aminonaphthalene to a 1,2dithiolane quenching moiety.32 In two-photon fluorescence, a fluorophore is excited by the
absorption of two photons which have half the energy and double the wavelength of a
single photon required to achieve that excitation. It is advantageous in allowing nondamaging and deeper imaging or tissue penetration, making the probe ideal for use in
imaging living organisms.49,

50

A 10 μM solution of TP-TRFS shows an ~ 15-fold

fluorescence increase at 490 nm in the presence of 50 nM TrxR within 3 h. The probe also
responds in Hep G2 cell lysates and shows diminished signaling in the presence of
auranofin or DNCB, the TrxR inhibitors. The fluorescence also increases in HeLa cells but
is weaker when TrxR is knocked out. TP-TRFS has a turn-on response in zebrafish, and is
thus the first probe to be used in detecting TrxR in living organisms. Two-photon
fluorescence imaging with TP-TRFS is also used to show declined TrxR in the brain of
mice with cerebral ischemic reperfusion injury. The data supports previously reported
studies on declining TrxR mRNA in the ischemic cerebral cortex, and may help in
understanding and in developing therapy for stroke.51
12

Bu and co-workers synthesized the probe TR-green (Figure 1.5) based on the
Michael addition of TrxR to the probe’s α,β-unsaturated ketone.52 This strong covalent
binding allows localized imaging of the enzyme and detection at nanomolar levels. The
mechanism of covalent binding via conjugate addition is the same as that of the known
TrxR inhibitor curcumin whereby the Sec498 and Cys497 residues are alkylated.53 TRgreen is synthesized by conjugating a coumarin fluorophore to a substituted furan ring
through an α,β-unsaturated ketone linker. This quenches the fluorescence through
intramolecular charge transfer (ICT) from the electron-rich fluorophore to the electron poor
aromatic ring through the extended conjugation. Conjugate addition to the Sec residue of
TrxR thus results in a fluorescence signal at 500 nm when TR-green is excited at 440 nm.
From a series of related probes synthesized in this study, TR-green is the most selective
and inhibitory for TrxR due to its 5-methylfuran moiety. Other probes can be attacked by
thiols through a similar Michael addition reaction.
TR-green

TPP2a

Figure 1.5. TR-green and the mitochondria targeting TPP2a, synthesized by Bu and co-workers.

The Bu group went on to create an improved inhibitor of TrxR2 that also functions
as an effective probe. TPP2a (Figure 1.5) is synthesized by conjugating a TrxR2 inhibitor,
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a furan analog of curcumin, to PPh3 for mitochondria targeting.54 Since TrxR is essential
in combating the effects of ROS in cancerous cells, its inhibition by TPP2a leads to
mitochondrial apoptosis in HeLa cancer cells. Interestingly, TPP2a is more active (IC 50 =
1.44 mM) against the cancer cells compared to the furan-curcumin inhibitor scaffold (IC50
= 24.22 mM).
TPP2a shows environmentally sensitive fluorescence, (λex = 440 nm, λem = 520 nm).
In the presence of thiols, the fluorescence is relatively low but increases in the presence of
BSA, TrxR, and other proteins such as Trx, glutathione reductase, tubulin, horseradish
peroxidase and superoxide dismutase.
To circumvent the non-specific signaling, the researchers cleverly coordinated the
β-diketone of TPP2a to a cupric ion, resulting in fluorescence quenching through the
disruption of conjugation. This results in selectivity for TrxR because the coordination of
cupric ion is weaker than preferential coordination of the β-diketone moiety with the K29
residue on the N-terminal of the TrxR active site. This binding is rationalized through
molecular docking of the probe onto the TrxR active site. The simulated data shows that
TPP2a attains a folded conformation in the hydrophobic active site and its β-diketone forms
two hydrogen bonds with the K29 residue of TrxR.
The Singh group designed carbon-dot based probes, Biotin-CD-Naph, that were
conjugated to a naphthalimide moiety through a disulfide linkage (Figure 1.6).55 This
makes a FRET pair that can be used in the selective targeting of thioredoxin reductase.
Carbon dots offer advantages such as good water solubility, inertness in biological
environments, photostability and easy surface functionalization.52, 56-58
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FRET pairs are advantageous in monitoring cell activities since the fluorescence
intensity of both the donor and the acceptor are considered, limiting the influence of
external factors, and allowing reproducibility of results. Carbon dots are the donors
whereas the 3-aminonaphthalimide fluorophore is the acceptor. The cystamine linkage
allows the donor and acceptor to be in a favorable distance for FRET transfer. Biotin is
also attached onto the CD surface, promoting endocytosis into cancer cells which
overexpress biotin receptors on their surfaces. The emission wavelength of CDs is known
to shift depending on the excitation wavelength; therefore, the emission energy can be
adjusted to suit that of the acceptor. This makes CDs ideal donors in a FRET pair.

Figure 1.6. Carbon dot-based TrxR probes synthesized by the Singh group ((Adapted with
permission from.55 Copyright 2017, American Chemical Society)
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The same property can be used to minimize background noise by shifting the excitation to
a higher wavelength.
In the presence of TrxR, the emission wavelength of the nanosensor at 565 nm
decreases whilst that at 450 nm (CD fluorescence) increases and plateaus in 80 min. The
reduction of the disulfide disrupts the FRET pair, and this results in fluorescence. The
probe is highly specific to TrxR and the fluorescence ratio I450/I565 increases steadily over
time with a limit of detection of 7.2 × 10-8 M. The nanosensor can image TrxR in human
breast cancer MCF-7 and cervical cancer HeLa cell lines. Cancer cells have about 70%
reduction in viability when treated with 100 μg/mL of the nanosensor. This is likely due to
the release of naphthalimide which resembles amonafide, a chemotherapeutic drug.
A second generation carbon dot-based probe, fCD-Cu2+, was synthesized and
evaluated for thioredoxin reductase screening by the Singh group via conjugation of 3-3′dithiodipropanoic acid (DTPA) moieties to the carbon dots (Figure 1.6).59 The blue
fluorescence of the CDs is quenched in the presence of Cu2+ ions via the chelating effect
of DTPA. The quenching mechanism is both static and dynamic and was based on the
transfer of electrons to the empty d orbitals of Cu2+. In the presence of TrxR, the disulfide
bonds are reduced and 3-mercaptopropinoic acid is released as a bidentate Cu2+ ion chelate,
in a cation displacement assay. When exposed to TrxR, a linear increase in the fluorescence
of the functionalized CDs is observed that plateaus after 100 min (λex = 340 nm, λem = 446
nm). The probe exhibits minimal toxicity to mammalian MCF-7 cells, but shows promising
cytoxicity to cancer cells, and is thus a promising theranostic tool
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Holmgren and co-workers evaluated two probes for their selectivity to mammalian
Trx and TrxR. The probes consisted of fluorescein isothiocyanate-labeled insulin (FiTCinsulin) and di-eosin-glutathione disulfide (Di-E-GSSG). They were prepared by
modifying the amino groups of GSSG with either FiTC or EITC.60 Di-E-GSSG is reduced
in the presence of Trx, TrxR and NADPH with a Km of 4.3 μM (λex = 520 nm, λem = 545
nm). This probe is shown to be a better substrate for Trx in comparison to TrxR due to the
large size and hydrophobicity of Di-E-GSSG that renders unfavorable binding to TrxR. DiE-GSSG is also a poor substrate for glutathione reductase (GR), even at high enzyme
concentrations. The Km for this GR reaction is 6.3 μM, with a low turnover.

FiTC-insulin has an average of two fluorophores per insulin molecule. When the
disulfide between the A and B chain of insulin is reduced, a fluorescence increase at 520
nm occurs (ex = 480 nm). When incubated with Trx, TrxR and NADPH, an increase in
fluorescence is also observed with a Km of 9.7 μM. FiTC-insulin can detect low levels of
Trx (4-20 nM) and TrxR (0.4-2 nM). Trx activity can be determined in U937, human
Burkitt’s lymphoma and K562 cell lines, and in homogenized skin biopsies, with
quantification of low levels of 0.35 ng Trx per μg of protein. FiTC-insulin can also be used
in determining Trx in serum and plasma. However, this is a relatively laborious method
involving initially reducing Trx with DTT and gel filtration to remove the excess DTT.
These studies have led to the development of a commercial TrxR assay kit.61
Recently, a unique off-on probe (MPSE) containing a benzoselazole conjugated to
a naphthalimide fluorophore (Figure 1.7) was synthesized to detect TrxR2.62 In the
presence of TrxR, the fluorescent MPSE (λem = 550 nm) reacts to form a non-emissive
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molecule, MP, due to PET quenching. MPSE serves as a theranostic via its ability to detect
mitochondrial TrxR and to trigger apoptosis in cancer cells. In apoptotic cells, damaged
mitochondria are phagocytosed by lysozymes and the acidic environment of the lysozomes
promotes a turn-on response of the probe (MP-H+ λem = 470 nm) such that the apoptotic
cycle can be monitored. The greater ICT in MPSE is responsible for the larger Stokes shift
and more red-shifted emission in comparison to MP-H+. The anticancer properties of this
probe are brought about when it triggers the expression of caspases and apoptotic proteins
while diminishing antiapoptotic protein levels. This is accompanied by an increase in the
release of ROS and inhibition of the MAPK signal transduction pathway that is essential
for cancer cell proliferation.

Figure 1.7. MPSE is reduced by TrxR in the prescence of NADPH to form the non-emissive MP.
This will fluoresce at a different wavelength under acidic conditions such as those in lysosomes.

Recently, the synthesis and evaluation of the first diselenide-based probe for the
selective detection of thioredoxin reductase was reported (Figure 1.8).63 This probe is the
subject of the next three chapters. It involves conjugation of a linear diselenide moiety, a
fluorescence quencher, to a fluorescent seminaphthorhodafluor. The design rationale was
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assisted by molecular docking studies onto the TrxR active site. The diselenide probe (1a)
has a more favorable binding energy of -11.1 kcal/mol compared to its disulfide analogue
(1b). Probe 1a shows potential as a scaffold for the development of theranostics, with rapid
turn-on kinetics.

Figure 1.8. The first diselenide probe for TrxR (1a) monitoring and its disulfide analog 1b.

Conclusion
The development of probes for monitoring TrxR activity is of significant current
interest due its role in cancer, oxidative stress and other significant disease states such as
ischemic reperfusion injury and Parkinson’s disease.31, 32 The Sec residue on the TrxR
active site gives this enzyme significantly greater catalytic efficiency and broader substrate
specificity compared to other oxidoreductase enzymes that utilize cysteine (Cys).6-9 This
unique residue allows targeted detection of TrxR using different fluorescent probes. Many
of the probes synthesized and evaluated to date target TrxR in cancer cell lines, and some
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also exhibit selective cytotoxicity and show promise as theranostics. There is still a need
to develop more probes with greater kinetic and theranostic properties. One such way
would be to design probes with a turn-on response that is not dependent on the cyclizationdriven step, as was done for Fast-TRFS. The TrxR-recognition moiety can be seleniumbased, as designed by the Strongin group, to allow rapid nucleophilic attack by TrxR which
leads to a faster response.62, 63 Molecular docking simulation-guided design of fluorescent
probes is an interesting avenue that can lead to more rapid discovery of the best probes
targeting TrxR. This has been utilized in the design of ethaselen, an orally administered
antineoplastic drug which is under phase I clinical trials and covalently binds to
overexpressed TrxR in cancers.64 Docking simulations have also been used to compare the
binding of diselenide and disulfide probes and related compounds onto the TrxR active
site.63, 65 The progress summarized herein should aid researchers in initiating additional
studies of enhanced TrxR probes and theranostics, and in broadening applications of TrxR
study to additional disease states.
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Chapter 2: Design and synthesis of diselenide-based probes
Material from this chapter has been published: T. J. Mafireyi, M. Laws, J. W. Bassett, P.
B. Cassidy, J. O. Escobedo and R. M. Strongin, Angewandte Chemie International
Edition, 2020, 59,15147-15151
The published paper has been modified

Research Focus
The aim of the work described in this chapter is to design, synthesize and evaluate turn
on fluorescent probes that are selective for TrxR. Successful candidates needed to meet the
following additional criteria:
1. High selectivity for TrxR versus other biological reductive species
2. Exhibit a distinct off to on fluorescence response in the presence of TrxR
3. Fast reaction kinetics
The design of prior fluorescent probes for TrxR has been biomimetic; i.e., based on the
biological mechanism of Trx reduction. As mentioned in Chapter 1, the disulfide based
TRFS series of probes synthesized by the Fang group have had the most application in this
regard.33, 43, 44, 47 These probes, however, have low binding affinity to the TrxR active site
(Km = 189 µM) and slow response times, requiring ~ 120-240 min to achieve maximum
fluorescence emission in the presence of TrxR.44 Km is defined as the concentration of
substrate required for half the maximum enzyme activity and it is inversely proportional
to enzyme-substrate affinity. This value is calculated assuming the steady state
approximations whereby the concentration of the enzyme substrate complex, [ES], is
constant.
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From this equation, Km is derived as:
Km = (k-1 + k2)/k1
A high value of k1 will lead to low Km and indicates a more stable enzyme-substrate
complex.66

Rationale for using diselenides
Our design incorporates a fluorophore conjugated to a diselenide quenching moiety.
We hypothesize that diselenides will lead to improved TrxR detection via exhibiting TrxR
selectivity along with enhanced kinetics. The general design is shown in Figure 2.1A,
(wherein X and Y = sulfur would be a control). The design rationale is based largely on the
proposed mechanism of the turn-on response that occurs via the SN2 type reduction of Trx.
The elimination step releases the caged fluorophore resulting in the turn-on fluorescence
(Figure 2.1B). Each step can be optimized by enhancing the electrophilicity of X and the
leaving group ability and nucleophilicity of Y. We thus proposed the probe design whereby
X=Se and Y=Se).
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Figure 2.1. A. Structure of the target probe consisting of a fluorophore conjugated to a quenching
moiety that also serves as the TrxR recognition site. B. Turn-on mechanism of the probe through a
reductive exchange reaction with TrxR. R = OH in the actual design described below.
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Electrophilicity
In the first step of the mechanism in Figure 2.1B, the diselenide serves as an
electrophilic center. Selenium has a larger atomic radius (115 pm) compared to sulfur (100
pm) and is capable of forming lower-energy hypervalent intermediates due to less steric
crowding.67 In addition, the empty σ* antibonding orbitals of Se are lower in energy and
thus accommodate extra electrons more favorably compared to S.68 For example, exchange
reactions of tollylithium with diphenyl diselenide occur 2 x 104 times faster compare to
diphenyl disulfide reactions.69 A computational simulation study also shows a kinetic and
thermodynamic preferential nucleophilic attack on the selenium in selenylsulfide bonds.67
In

one

comparative

study

whereby

cystamine

reduced

selenocystamine

to

hemiselenocystamine and then cystamine, the nucleophilic attack at Se occured at a rate 4
orders of magnitude higher than for sulfur.70
Leaving group ability
The reduction of the -X-Y- bond results in Y- as a leaving group. We reasoned that
formation of the selenolate (Y-) will be more facile than formation of a thiolate at
physiological pH due to the lower pKa of selenols (≈ 5.2) compared to thiols (≈ 8.5).68 The
relatively higher polarizability of Se also makes it a better leaving group in comparison to
S.71
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Nucleophilicity
Upon cleavage of X-Y and formation of Y-, an addition-elimination reaction
follows. The reaction should be more favorable when Y is selenium since selenolates are
nearly ten times more nucleophilic than thiolates.71, 72 They are also ca. 130-390 fold more
reactive with disulfides and diselenides under neutral conditions in comparison to thiols.44,
70

Selenium is therefore a Janus-faced element that offers both better electrophilicity
and nucleophilicty. The larger size (3.8Å) and polarizability of Se compared to S (2.9Å)
make it a good nucleophile in aqueous media. The lower pKa of Se also contributes to the
enhanced nucleophilicity at physiological and acidic pH. Hence, formation of the
selenocarbamate and uncaging of the fluorophore will occur more efficiently in comparison
to a thiocarbamate analogue.
The combined effect of all three factors works towards fast exchange reactions
when a diselenide moiety is used instead of a disulfide. This is supported by a study in
which

selenol/diselenide

(selenocysteamine/selenocystamine)

and

thiol/disulfide

(cysteamine/cystamine) reactions were monitored by 1H NMR. At physiological pH, the
selenol/diselenide exchange reactions are 1.2 x 107 times faster than thiol/disulfide.73
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Docking of probe on the TrxR active site
Synthetic targets for TrxR were designed. These molecules were investigated by
docking onto the TrxR active site using Autodock Vina. TrxR interacts with diselenides
via the Sec residue on its C-terminal (Sec498).74, 75 Binging energy (ΔGbind) values were

Figure 2.2. Lowest energy conformation of diphenyl diselenide docked onto the TrxR active site.
The distance from Sec498 (U498) to the diselenide bond is shown, as well as aromatic amino acid
residues that interact with the (PhSe)2 rings. (Adapted wth permission from65, Copyright, Royal
Society of Chemistry)

obtained, together with docking distances of the diselenide to Sec498. Figure 2.2 shows a
model example using diphenyl diselenide whereby binding is enhanced via non covalent
interactions between aromatic rings of the diselenide compound and the hydrophobic
residues on the enzyme active site such as W407 and L409.65
Geometry optimizations for the diselenide probes were performed using the semiempirical PM7 Hamiltonian included in MOPAC2016.76 Since Gasteiger charges were not
available for selenocompounds, partial charges (PM7) were used through the MOZYME
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method included in MOPAC 2016, as previously done by Sudati et al.65 The MOPAC
output files were converted to pdbqt files ready for docking using Openbabel.77 The crystal
structure of rat (Rattus norvegicus) TrxR1 expressed in Escherichia Coli was obtained
from the RCSB Protein DataBank (http://www.rcsb.org/pdb/), PDB entry code: 1H6V.
Only chains A and B were isolated from the crystal structure and used for further studies.
The cysteine (Cys498) residue of TrxR1 was replaced by selenocysteine (Sec498 or U498)
using UCSF Chimera to accommodate for selenium that is incorporated onto the enzyme
active site. Based on the pKa, the Se in the residue was set as the deprotonated form (Se-)
with a partial charge (Gasteiger) of -0.814.78 To prepare for docking, water molecules were
excluded from the structure and hydrogen atoms were added to the enzyme structure via
Autodock Tools. The grid was centered at the Se atom (x = 2.930; y = 10.909; z = 156.398)
with a box size of 30 × 30 × 30 Å and an exhaustiveness of 8. The docking simulations
were carried out using Autodock Vina 1.1.2.
The optimized probe structures and their binding free energies (ΔGbind) are shown
in Table 2.1. The distances from the selenium atom in the Sec residue of TrxR1 to the
selenium atoms on the probes were also measured.
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Table 2.1. Proposed diselenide-based candidates and their relative binding energies to the TrxR
active site based on our simulations.

Probe #

Structure

ΔGbind (kcal/mol)

1a

-11.1

2a

-11.0

3a

-10.5

4a

-10.5
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5a

-12.5

6a

-10.2

7a

-10.7

8a

-10.6
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9a

-10.3

10a

-10.5

The disulfide analogues of the compounds in Table2.2 were also docked and the results are
shown in Table 2.2.
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Table 2.2. Disulfide-based candidates and their relative binding energies to the TrxR active site
based on our simulations. They all show lower binding affinity relative to the diselenide analogues.

Probe #

Structure

ΔGbind (kcal/mol)

1b

-9.6

2b

-9.7

3b

-9.9

4b

-9.8
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5b

-10.1

6b

-9.5

7b

8b

-9.8

-9.5
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9b

-9.4

10b

-8.9

Compound 5a (Table 2.1) had the strongest binding affinity to the enzyme active site.
However, this molecule (in the carboxylate form) is inherently fluorescent at physiological
pH. Compound 1a (-11.1 kcal/mol) was therefore chosen as the first candidate for further
analysis. Note that its disulfide analogue (1b) exhibits a lower binding affinity of -9.6
kcal/mol (Figure 2.3).
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A

B

Figure 2.3. Docking simulations for: (A) Optimized structure of probe 1a and (B) Probe 1b onto
the active site of TrxR1. The distances between the Se atom on the Sec residue (U498a) and the
diselenide and disulfide bond atoms are shown. Probe 1a has a binding energy of -11.1 kcal/mol
whereas that probe 1b is -9.6 kcal/mol.

The favorable binding of 1a compared to 1b showed that diselenide compounds are
better TrxR candidates compared to the disulfides. Binding is assisted by Van der Waals
interactions between the amino acids on the enzyme active site and the probe as shown for
probe 10b below.
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Figure 2.4. Docking simulations showing the Van der Waals interactions (yellow lines) of probe
10b with some amino acids on the active site of TrxR1. These interactions are utilized in calculating
binding energy values.

For comparison with other probes published in literature, docking simulations were
also run for the TRFS series of probes synthesized by the Fang group and they had binding
energies ranging from -7.7 to -8.5 kcal/mol.
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Table 2.3. Binding affinity values for the TRFS series of probes.

Probe

Structure

ΔGbind (kcal/mol)

Mito-TRFS

-7.9

TRFS-green

-8.2

TRFS-red

-8.4
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Fast-TRFS

-8.5

TP-TRFS

-7.7

With this data, we went on to synthesize compounds 1a and 1b for further application in
TrxR detection.
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Synthesis

Scheme 2.1. Synthesis of probes 1a and 1b.
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Synthesis of 8-methoxynaphthalen-1-ol, 7.

Under N2, 1,8-dihydroxynaphthalene (8) (1.00 g, 6.24 mmol) and Cs2CO3 (3.05 g,
9.36 mmol) were suspended in 10 mL of acetone. CH3I (390 μL, 0.89 g, 6.24 mmol) was
added in one portion and the mixture refluxed for 4 h. The mixture was cooled to room
temperature, diluted with 20 mL of H2O and the pH adjusted to 1 by adding HCl. Liquidliquid extraction was then done with EtOAc (2 × 50 mL) and the organic fractions
combined and dried over anhydrous Na2SO4. The Na2SO4 was filtered off and the solvent
removed under vacuum. The crude solid was purified by flash chromatography (silica,
EtOAc:Hexanes 1:3). Compound 7 was obtained as a white solid (0.92 g, 84 %). ESI-MS
(m/z) calc for C11H11O2 [M + H]+: 175.0736, found: 175.0761. 1H NMR (400 MHz,
DMSO-d6) δ 9.39 (s, 1H), 7.45 - 7.30 (m, 4H), 6.94 (dd, J = 7.6, 1.2 Hz, 1H), 6.79 (dd, J
= 6.6, 2.1 Hz, 1H), 4.03 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 156.34, 154.33, 136.73,
127.77, 126.64, 121.42, 118.87, 114.56, 110.62, 104.95, 56.01, 40.05.
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Synthesis of 2-(4-amino-2-hydroxybenzoyl)-benzoic acid, 3.

Rhodamine 110 hydrochloride (4) (0.20 g, 0.55 mmol) and NaOH (0.38 g, 9.27
mmol) were dissolved in 180 µL of H2O. The mixture was heated at 160 °C under reflux
for 2 h, followed by the addition of 0.5 mL of 50% NaOH. After heating at 160 °C for
another hour, 10 mL of H2O was added to the reaction and the pH was adjusted to 1 with
HCl. The solution was extracted with EtOAc (2 x 50 mL) after which the solvent was
removed under vacuum to obtain a yellow solid which required no further purification
(0.13 g, 94 % yield). ESI-MS (m/z) calc for C14H12NO4 [M + H]+: 258.0761, found:
258.0721. 1H NMR (400 MHz, DMSO) δ 13.05 (s, 1H), 12.61 (s, 1H), 7.95 (d, J = 7.7 Hz,
1H), 7.68 (t, J = 7.5 Hz, 1H), 7.60 (t, J = 7.6 Hz, 1H), 7.37 (d, J = 7.47 Hz, 1H), 6.72 (d, J
= 8.5 Hz, 1H), 6.45 (s, 2H), 6.02 (d, J = 10.1 Hz 2H).
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C NMR (101 MHz, DMSO) δ

198.31, 166.92, 164.98, 156.82, 140.07, 134.48, 131.95, 129.84, 129.69, 129.31, 127.68,
109.79, 106.48, 98.16.
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Synthesis of 2,2'-diselanediylbis(ethan-1-ol), 5.

Se (0.50 g, 6.33 mmol) and NaBH4 (0.50 g, 13.21 mmol) were dissolved in 25 mL
of H2O. This vigorous reaction was stirred over 15 min. An additional 0.5 g of Se was
added to ensure that all the NaBH4 reacted. Excess Se was filtered off and the reddishbrown solution of Na2Se2 was transferred to a round-bottom flask. The flask was purged
with N2 and 0.89 mL (12.45 mmol) of 2-bromoethanol (6) in anhydrous THF was added to
the Na2Se2. The reaction was run at 50 °C for 6 h, followed by liquid-liquid extraction with
DCM and subsequently silica gel chromatography with 1:1 DCM:EtOAc to give 5 in 38 %
yield. ESI-MS (m/z) calc for C4H9Na2O2Se2 [M + 2Na - H]+: 294.8723, found: 294.8991.
1

H NMR (400 MHz, DMSO) δ 4.82 (t, 2H), 3.62 (t, 4H), 2.78 (t, 4H). The purity of the

compound was also confirmed via HPLC.

Synthesis of 10-amino-1-methoxy-3'H-spiro[benzo[c]xanthene-7,1'-isobenzofuran]3'-one, 2.

Compound 3 (150 mg, 0.58 mmol) and compound 7 (152 mg, 0.88 mmol) were
dissolved in 1 mL of methanesulfonic acid, then 1 mL of TFA was added. The mixture was
stirred for 16 h at 80 °C and then cooled down to rt and poured into 50 mL of DI water.
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The mixture was then neutralized to pH 6-7 by portion wise addition of solid NaHCO3. A
precipitate was formed and filtered, washed with water (25 mL), and then air dried. The
compound was purified using silica gel chromatography with DCM:MeOH 9:1 as the
eluent, with a 94 % yield. ESI-MS (m/z) calc for C25H18NO4 [M + H]+: 396.1230, found:
396.1126. 1H NMR (400 MHz, DMSO-d6) δ 8.03 (m, 1H), 7.79 (m, 1H), 7.74 (dd, J = 7.5,
1.1 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H), 7.48 (dd, J = 13.3 , 8.8 Hz, 2H), 7.28 (m, 1H), 7.16
(d, J = 7.7 Hz, 1H), 6.42 (m, 2H), 5.76 (s, 2H), 5.69 (s, 2H), 4.06 (s, 3H). 13C NMR (101
MHz, DMSO) δ 168.83, 157.04, 153.02, 151.59, 151.31, 148.04, 136.49, 135.58, 130.04,
128.46, 128.17, 126.22, 124.58, 124.42, 124.14, 123.19, 120.30, 114.95, 112.83, 111.72,
108.26, 104.64, 99.48, 84.29, 56.42.

Synthesis of 2-((2-hydroxyethyl)diselaneyl)ethyl (1-methoxy-3'-oxo-3'Hspiro[benzo[c]xanthene-7,1'-isobenzofuran]-10-yl)carbamate, 1a.

Compound 2 (100 mg, 252.26 µmol) was dissolved in 20 mL of DCM. Saturated
aqueous NaHCO3 (5 mL) was added and the biphasic mixture was cooled in an ice bath
while being stirred. Triphosgene (20 mg, 84 µmol) was added to the mixture in one portion
and the reaction was stirred for 15 min. The organic layer was removed, and the aqueous
layer extracted with DCM (3 × 20 mL). 2-hydroxyethyl diselenide (32 mg, 129 µmol) was
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dissolved in DCM:THF 1:1, added to the reaction mixture containing 2, and stirred
overnight. Probe 1a was purified using Reverse-phase HPLC, using a C-18 column with
water:acetonitrile gradient elution over 40 minutes (4 % yield). ESI-MS (m/z) calc for
C30H24NO7Se2- [M - H]- : 669.9786, found: 669.9788. 1H NMR (400 MHz, DMSO-d6) δ
10.11 (s, 1H), 8.08 (dd, 7.5, 3.1 Hz, 1H), 7.83 – 7.73 (m, 3H), 7.57 (t, J = 8.0 Hz, 1H),
7.48 (dd, J = 13.3 , 8.8 Hz, 2H), 7.28 (m, 1H), 7.16 (d, J = 7.7 Hz, 1H), 6.42 (m, 2H), 5.76
(s, 2H), 5.69 (s, 2H), 4.06 (s, 3H)
Table 2.4. HPLC gradient elution of compound 1a on a C-18 reverse phase column

Time (min)

% Water (0.1 % Formic Acid)

0
5
10
15
18
24
26
28

95
75
50
45
43
40
30
5

% Acetonitrile (0.1% Formic
acid)
5
25
50
55
57
60
70
95

ESI-MS (m/z) calc for C30H24NO7Se2- [M - H]- : 669.9786, found: 669.9884. The purity
was confirmed through HPLC.

Figure 2.5. Chromatogram for the HPLC purification of 1a, retention time 30.5 min.
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Synthesis of 2-((2-hydroxyethyl)disulfanyl)ethyl(1-methoxy-3'-oxo-3'Hspiro[benzo[c]xanthene-7,1'-isobenzofuran]-10-yl)carbamate 1b.

Compound 2 (100 mg, 252.26 µmol) was dissolved in 20 mL of DCM. Saturated
aqueous NaHCO3 (5 mL) was added and the biphasic mixture was cooled in an ice bath
while being stirred. Triphosgene (25 mg, 84 µmol) was added to the mixture in one portion
and the reaction was stirred for 15 min. The organic layer was removed, and the aqueous
layer extracted with DCM (3 × 20 mL). 2-hydroxyethyl disulfide (20 mg, 129 µmol) was

Figure 2.6. Chromatogram for the HPLC purification of 1b, retention time 30.5 min

dissolved in DCM:THF 1:1, added to the reaction mixture containing 2, and stirred
overnight. Probe 1b was purified using Reverse-phase HPLC, using a C-18 column with
water: acetonitrile gradient elution (10 % yield). ESI-MS (m/z) calc for C30H24NO7S2 [M
+ H]+ : 576.1172, found: 576.1787. 1H NMR (400 MHz, DMSO-d6) δ 10.05 (s, 1H), 8.07
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(dd, 7.5, 3.1 Hz, 1H), 7.82 – 7.57 (m, 3H), 7.56 (t, J = 8.0 Hz, 1H), 7.48 (dd, J = 13.3 ,
8.8 Hz, 2H), 7.21 (m, 1H), 7.16 (d, J = 7.7 Hz, 1H), 6.42 (m, 2H), 4.07 (s, 2H), 3.71 (s,
2H), 2.51 (s, 7H)The purity was confirmed through HPLC.
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Chapter 3: Quenching mechanism and turn-on response of probes
Material from this chapter has been published: T. J. Mafireyi, M. Laws, J. W. Bassett, P.
B. Cassidy, J. O. Escobedo and R. M. Strongin, Angewandte Chemie International
Edition, 2020, 59,15147-15151
The published paper has been modified

Fluorescence mechanism of 2
The synthesized compounds 1a and 1b had a dull yellow color and were nonfluorescent. The precusor, 2, was however a bright red solid which was fluorescent in
solution. Therefore, to understand how 1a and 1b are quenched, there is need to understand
how molecule 2 fluoresces. A 10 µM solution of 2 was dissolved in 0.3 % DMSO and 50
mM TE buffer, pH 7.4. UV/Vis and excitation and emission data were collected and the
fluorophore had λabs = 531 nm and λem = 580 nm with a molar absorptiity of 9.71 x 103 M1

cm-1 (Figure 3.1).
The fluorescence mechanism of 2 can be represented by the Jablonski digaram

(Figure 3.2). When the fluorophore absorbs light from an external source, electrons will go
from the ground state (S0) to a higher level singlet excited state. There are multiple energy
levels or excited states that can be attained by the fluorophore, depending on the energy of
the light source. Since the fluorophore is unstable at high energy levels, it eventually attains
the lowest energy excited state through relaxation in a process called internal comversion.
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Figure 3.1 Absorption spectrum of 2 with λabs = 531 nm and emission spectrum with λem = 580 nm.
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Figure 3.2. The Jablonski diagram showing the excitation of a fluorophore from the ground state
(S0) to an excited state (S1). Internal conversion then occurs (purple arrow), followed by emission
to the ground state.

The excited fluorophore will then relax to the ground state through a radiative
process that emits light at a longer wavelength than the excitation wavelength.79 We
hypothesized that the quenching of probes 1a and 1b was brought about by the diselenide
and disulfide groups respectively. However, one could argue that the acylation of the
terminal NH2 group of the fluorophore may quench fluorescence via the electron
withdrawing carbonyl. This acts in competition with the conjugation and opening of the
lactone ring which is necessary for fluorescene to occur. It is worth noting that the lactone
ring can also be opened by increasing the pH, hence all comparisons are done in a buffered
environment at pH 7.4.
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Figure 3.3. A: Conjugation of electrons and lactone ring opening in 2, which leads to fluorescence.
B: Delocalization of the nitrogen lone pair into the carbonyl group, which may lead to fluorescence
quenching.
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Elucidating the quenching mechanism of acylated rhodamines
As a control, probe 1c was synthesized by acylating the -NH2 group (Figure 3.4).

Figure 3.4. Synthesis of 1c through acylation of the NH2 group of 2.

150 mg (0.38 mmol) of 2 was dissolved in 20 mL of DCM and acetic anhydride (54 µL,
0.57 mmol) was added dropwise, together with pyridine (46 µL, 0.57 mmol). The mixture
was stirred for 18 h, after which the solvent was removed under vacuum. Purification was
done using reverse phase HPLC using a C-18 column with a water:acetonitrile gradient
and elution over 35 min (24 % yield). ESI-MS (m/z) calc for C25H18NO4 [M + H]+:
396.1230, found: 396.1126.
Table 3.1. HPLC gradient elution of compound 2 on a C-18 reverse phase column

Time (min)
0
5
10
15
18
24
26
28

% Water (0.1 % Formic Acid)
95
75
50
45
43
40
30
5

% Acetonitrile (0.1% Formic
acid)
5
25
50
55
57
60
70
95
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Probe 1c had an orange color. UV/Vis and fluorescence spectra were acquired (Figure
3.5).
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Figure 3.5. Absorption spectrum of probe 1c with λabs = 538 nm and the emission spectrum with
λem = 575 nm

From these results, it can be concluded that acylation of the amine was not
responsible for the quenching, and that the diselenide and disulfide groups contributed
significantly in this regard in 1a and 1b.
Fluorescence quenching can occur by one of these mechanisms:
1. Förster resonance energy transfer (FRET), based on dipole-dipole interactions of
the donor and the acceptor. This is possible if the emission wavelength of the donor
overlaps with the absorption wavelength of the acceptor.
2. Random collisional quenching that causes dissipation of energy from the
fluorescent molecule.
3. Proton transfer between the fluorophore and the quencher.

51

4. Increased vibrational coupling between the excited state and the ground state of the
fluorophore, brought about by the quencher.
It has been previously shown that the fourth mechanism occurs in proteins that have
cystine residues whereby the disulfide linkage acts as a sink for energy dissipation.
Fluorescent aromatic amino acids such as tryptophan are quenched due to enhanced
vibrational coupling between the excited singlet state and the ground state.72 Free
sulfhydryl groups have also been shown to cause a decrease in the fluorescence of probes,
but not as efficiently as disulfides. The quenching is likely a result of short range
interactions, resulting in energy dissipation. The efficiency of this quenching decreases as
the distance between the quencher and the fluorescent molecule increases.80
Random collisional quenching has been ruled out as a viable mechanism by a study
that utilized free disulfide molecules, ethanol-S-S-ethanol and butanol-S-S-butanol. These
two diols were mixed with fluorescent amino acids, tryptophan and tyrosine, but no
quenching was observed and the amino acids remained fluorescent.72 Another independent
study showed how cleavage of a cystine disulfide bond in DsbA, an oxidoreductase protein,
resulted in fluorescence of tryptophan within the same protein.81 This tryptophan is situated
20 Å from the disulfide, eliminating the possibility of static quenching. If the disulfide
probe is moved further away from tryptophan, fluorescence successively increases until no
more quenching is observed. Optimal quenching occurs when the two moieties are within
a Van der Waals distance of less than 7 Å. Disulfide bonds that have rotational freedom
also potentially affording them the capability to reach the Van Der Waal’s distance for
quenching.80
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Selenium has more efficient distance-dependant fluorescence quenching properties
compared to sulfur. In a study in which the calmodulin protein was bound to
selenomethionine, methionine and leucine, tryptophan fluorescence was quenched in the
order Se > S > C through dynamic (collisional) or static quenching. The chalcogens Se and
S were incorporated into a benzoquinone framework (7a and 7b, respectively) and an
absorption maxima was observed aound 355 nm due to π-π* transitions, with fluorescene
at 440 nm. Quantum yields were higher for the sulfur compounds compared to seleniumcontaining compounds due to triplet state population via intersystem crossing facilitated
by Se (Figure 3.6). Therefore, the deactivation between states of the same multiplicity is
disfavored, including PET quenching. Oxidizing the selenium molecules resulted in no
change in the UV-Vis spectrum but the fluorescence increased over time, showing
deactivation of the chalcogen quenching.82, 83
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Figure 3.6. Fluorescence spectra of benzimidazo[1,2-a]quinoline derivatives (7a and 7b), showing
enhanced quenching in the selenium-bearing compound. Adapted with permission from 5,
Copyright, 2019, Royal Society of Chemistry.

Selenium also increases quenching through the heavy atom effect, which involves
an enhancement in the rate of a spin-forbidden process.84 The heavy Se nucleus influences
the spin of the excited electron through mixing its vacant d orbitals with the fluorophore
orbitals.85 This improves spin orbital coupling resulting in intersystem crossing to populate
the triplet state. The triplets can lose energy through phosphorescence but this is
uncommon at room temperature due to spin forbidden transitions. Dissipation of energy
through collisional quenching with other species or through a non radiative decay can also
occur.
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Figure 3.7. Jablonski diagram showing the proposed electronic transitions between the fluorescent
molecule and the quencher. After the molecule gets excited, intersystem crossing occurs to the
triplet state and this is facilitated by the quenching moiety. Energy is then lost non-radiatively due
to increased energy sinks.

Experimental data derived from studies with probe 1a however contradicted the
above mechanism since the absorption wavelength of the fluorophore should not change.
Probe 1a however only had maximum absorption in the UV region, which is in stark
contrast to 2, which absorbed in the visible region. The diselenide group therefore results
in static quenching of the fluorophore, whereby a complex is formed that has unique
absorption properties. When excited, this complex will also have a non radiative loss of
energy and is therefore not fluorescent.
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Figure 3.8. A. Absorption spectrum of probe 1a, showing absorption in the UV region.
B. Static quenching mechanism of the diselenide probe whereby the fluorophore and the quencher
form a non-fluorescent complex.
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Reduction of compound 1a with Dithiothreitol (DTT)
10 µM of 1a in pH 7.4 buffer was mixed with equimolar dithiothreitol, a, reducing
agent that can reduce diselenides and disulfides.86 There was an instantaneous turn-on
response of the probe to give a yellow fluorescent solution (λabs = 531 nm, λem = 580 nm)
(Figure 3.9). Maximum fluorescence was achieved promptly and the compound was not
bleached during storage. Disulfide probes on the other hand take up to 120 min to achieve
maximum fluorescence, even when treated with strong reducing agents such as TCEP.52
These results show the potential of using 1a to image TrxR1.
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Figure 3.9 A: Absorption spectrum of 1a with λabs = 531 nm and λem = 580 nm. B: Probe 1a without
and with DTT. Once DTT is added, a distinct fluorescence is observed.
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The mechanism promoting this optical response is depicted in Scheme 3.1. Shown
in the scheme is the same mechanism, but whereby we envision that TrxR, rather than DTT,
will elicit a turn-on response for 1a.

Scheme 3.1. Proposed turn-on mechanism of probe 1a in the presence of TrxR1 and NADPH.
Nucleophilic attack of the diselenide occurs through the TrxR1 Sec residue. The selenolate formed
attacks the carbamate carbonyl, releasing an oxaselenolanone heterocycle and fluorescent 2.

To confirm the turn-on mechanism of 1a, 50 µM solutions of 1a were mixed with
10 µM of DTT and the reactions were monitored via HPLC-MS after 5, 10, 15 and 20 min
incubation periods. The HPLC was run on a reverse phase C-18 column (Poroshell 120,
4.6 x 50 mm, 2.7 micron, Agilent Technologies) with a water:acetonitrile gradient mobile
phase.
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Table 3.2. Gradient elution of the 1a and DTT reaction mixture.

Time (min)
0
10

% Water (0.1% Formic
acid)
95
5

% Acetonitrile (0.1% Formic
acid)
5
95

The peak for 1a diminished whereas that of 2 increased with time. The proposed
selenolate intermediate (Figure 3.10) was also observed, and its peak intensity increased
with time. Mass spectra corresponding to each of the peaks is shown in Figure 3.11, 3.12
and 3.13.
1a

Intermediate

2

59

Reaction progress
Figure 3.10: HPLC traces of 1a (50 µM) with DTT (10 µM) showing the decline in the amount of
the probe and an increase in the intermediate and 2 after 5, 10, 15 and 20 min (from top to bottom).
The peaks represent (from left to right); 2, intermediate selenolate and 1a.
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Figure 3.11: ESI positive mode spectrum of intact compound 1a before reduction by DTT
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Figure 3.12: ESI positive mode spectrum of the intermediate formed after cleavage of the
diselenide bond by DTT
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Figure 3.13: ESI positive mode spectrum of fluorescent compound 2 formed after cleavage of the
diselenide bond by DTT.
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Chapter 4: Enzymatic assays and cell studies

Material from this chapter has been published: T. J. Mafireyi, M. Laws, J. W. Bassett, P.
B. Cassidy, J. O. Escobedo and R. M. Strongin, Angewandte Chemie International
Edition, 2020, 59,15147-15151
The published paper has been modified

Reactivity of 1a with TrxR1
This chapter focuses on the reactivity of the diselenide probe 1a with TrxR1.
Thioredoxin reductase from rat liver was obtained from Sigma-Aldrich (St. Louis, MO)
and used without further purification. Ultrapure water from a Milli-Q system was used
throughout the experiment for all aqueous systems.
TrxR1 was quantified using a procedure adapted from the Sigma Aldrich technical
service manual. This protocol describes the TrxR1 activity in terms of the reduction of
DTNB2- to TNB2- in the presence of NADPH. One unit of TrxR1 is the amount needed to
catalyze one μmole of NADPH per min.87 NADPH was quantified based on its absorption
at 340 nm and dividing this by the molar absorptivity.
A 10 μM solution of 1a was prepared, together with EDTA (10 mM), BSA (0.2
mg/mL) and NADPH (0.24 mM) in a 100 mM, pH7.4 phosphate buffer. 0.06 units of
TrxR1 were added and the reaction immediately monitored for the change in fluorescence
(λex = 531 nm; λem = 580 nm) as well as the depletion of NADPH (λabs = 340 nm). The
formation of the fluorescent product 2 was also followed by measuring the absorption at
531 nm through the course of the reaction. All measurements were made in a 96-well plate
over 10 min, using a Synergy H1 microplate reader (BioTek, Winooski, VT) and the
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accompanying Gen5TM software, version 2.05. A drastic increase in absorption at 531 nm
and fluorescence at 580 nm was observed, accompanied by a decrease in absorption at 340
nm (Figure 4.1, 4.2 and 4.3).

Absorbance (531 nm)
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Figure 4.1 Increase in absorbance at 531 nm after reacting 1a with TrxR1, showing the formation
of the fluorescent product.
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Figure 4.2. Fluorescence increase versus time for probe 1a reacting with TrxR1. The reaction
mixture contained 10 μM 1a, 0.06 units TrxR1 in the presence of EDTA (10 mM), BSA (0.2
mg/mL) and NADPH (0.24 mM).
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Figure 4.3 Absorbance at 340 nm versus time, showing the decrease in the amount of NADPH
during the reaction of TrxR1 with 1a. NADPH is needed as a reducing equivalent for TrxR1. The
reaction mixture contained 10 μM 1a, 0.06 units TrxR1 in the presence of EDTA (10 mM), BSA
(0.2 mg/mL) and NADPH (0.24 mM).

The reaction between the diselenide probe and TrxR1 was instantaneous. A separate set of
assays was set up by varying the concentration of enzyme from 0 to 0.12 units with 20 µM
of 1a (Figure 4.4).
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Figure 4.4. Fluorescence emission vs time for 20 μM 1a (substrate) under different enyzme
concentrations. (λex = 531 nm; λem = 580 nm).
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Figure 4.5 Absorbance at 340 nm vs time showing the depletion of NADPH as TrxR1 reacts with
1a.
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For 0.12 units of the enzyme (~100 nM TrxR1), the reaction started to plateau
within 30 mins. This is favorable in comparison to previously reported disulfide probes
which require 120 – 240 mins to plateau.33, 43, 47, 88 Omitting either the NADPH, probe or
enzyme from the reaction mixture resulted in no spectral changes, showing that all three
are indispensable for the reaction.
Kinetic studies were also carried out over 20 min for six concentrations of 1a,
ranging from 0 µM to 20 µM, in the presence of 0.12 units of TrxR1 (Figure 4.6). The first
trials were done with 0.06 units of enzyme, but these reactions failed to provide useful
results, hence the concentration was increased.
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Figure 4.6: Fluorescence intensity vs time for 1a (0 – 20 µM) with 0.12 units of TrxR1.

The initial reaction velocity was calculated for the different reaction mixtures, and
this was plotted against the probe concentration to give a Michaelis-Menten plot (Figure
4.7).
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Figure 4.7. Reaction rate vs substrate concentration to illustrate the change in the speed of the
reaction over time for each substrate concentration. Km for the reaction was 15.89 μM. Degrees of
freedom = 4. Absolute sum of squares = 6.335. Sy.x = 1.258

Using PrismTM, the Vmax (maximum reaction velocity) was calculated to be 80.22 RFU/s
whereas the Km was calculated to be 15.89 µM. This low Km value is evidence of
relatively high affinity between the TrxR1 enzyme and probe 1a.

TrxR1 selectivity assays
The selectivity of TrxR1 for probe 1a was evaluated against other known biological
reducing agents. None afforded a significant change in fluorescence comparable to that of
TrxR1 (Figure 4.8). Minimal interference was observed with glutathione but TrxR1
promoted ca. 20 times greater fluorescence. Moreover, the experiments were run at
millimolar (physiological cellular) levels of GSH but with minimal amounts of TrxR1 (ca.
100 nM).
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Figure 4.8. Fluorescence responses of probe 1a upon 20 min incubation with TrxR1 and other
potential biological reducing species (Cys = cysteine, Hcy = homocysteine, GSH = glutathione).

Cell imaging
HCC827 (lung adenocarcinoma) cells were seeded in a 96-well plate and cultured
overnight in RPMI medium 1640 (1x) with L-glutamine and standard serum
supplementation at 37°C in a humidified atmosphere of 5 % CO2. After 24 h, the media
was aspirated and cells were treated with 2,4-dinitrochlorobenzene (DNCB) with
concentrations (0, 20, 40 and 60 μM) for 1 h. DNCB is an irreversible electrophilic inhibitor
of TrxR.89, 90 Half of the cells were treated with probe 1a (10 μM) while the rest were
treated with probe 1b (10 μM) for 1 h. Each treatment was done in triplicate to give a total
of 24 wells. The cells were rinsed three times with Dulbecco’s Phosphate Buffered Saline
(1x) to remove the unbound probe. Imaging was carried out using a Zeiss inverted
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microscope with an Axioscan fluorescence camera. Fluorescence was apparent in cells
treated with probes 1a and 1b (Figure 4.9). Control cells exhibited no detectable
fluorescence whereas those treated with the TrxR inhibitor DNCB had diminished
fluorescence.

HCC827 cells

Cells + Probe 1a

DNCB + Cells + Probe 1a

HCC827 cells

Cells + Probe 1b

DNCB + Cells + Probe 1b

Figure 4.9: Live cell imaging of HCC827 cells (i) Untreated controls (ii) Treated with 10 µM of
either 1a or 1b and (iii) Treated with 40 μM DNCB and 10 µM of either 1a or 1b. After 1 h, the
untreated cells showed no fluorescence whereas those treated with the probes fluoresced.
Pretreating the cells with DNCB before introducing the probes resulted in diminished fluorescence.
This fluorescence was quantified and was higher for 1a (15805 R.F.U) compared to 1b (9903
R.F.U).
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The fluorescence intensity was quantified, and probe 1a had a relative fluorescence
intensity nearly double that for 1b (Figure 4.10).
1a (Diselenide)
1b (Disulfide)
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Figure 4.10: Fluorescence response of HCC827 cells treated with probe 1a and 1b. Cells were
initially incubated with varying concentrations of DNCB (a known TrxR1 inhibitor) for 1 h, after
which they were treated with 10 μM of 1a and 1b for another hour. Cells treated with 1a had
significantly higher fluorescence compared to 1b. In both cases, the fluorescence decreased with
increase DNCB concentration.

MTS cytotoxicity assays were carried out for probe 1a since selenium is known to
be both carcinogenic and anticarcinogenic.91

This assay is based on the NADPH-

dependent reduction of a tetrazolium compound by viable cells through dehydrogenase
enzymes. The product is quantified by measuring the absorbance at 490-500 nm and this
colorimetric change will determine cell viability. SK-MEL-5 and A375 human epithelial
malignant melanoma cell lines were used to evaluate the cytotoxicity of 1a. Initial
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treatment of these cells with 30 µM of probe 1a led to complete cell death therefore this
concentration was not included for either cell line.
The cell lines were plated and allowed to recover for 24 h then treated with the
indicated concentrations for 24, 48, or 72 h. Cells were visualized prior to application of
MTS/media solution to ensure that reductive capacity was an acceptable proxy for cell
viability in this context. Both cell lines were grown and plated in Advanced DMEM
supplemented with 2% FBS, GlutaMAXTM, and penicillin-streptomycin. Cells were plated
at 8,000 cells/well for 24 h recovery, and 6,000 cells/well for 48- and 72-hour recovery.

Table 4.1. Cell line treatment with probe 1a to determine cytotoxicity.

Cell line

A375

SK-MEL-5

Probe 1a concentrations (µM)

1; 3; 5; 7; 10; 30

0.3; 1; 1.5; 2.25; 3; 10

Treatment period (h)

24; 48; 72

24; 48; 72

IC50 values (µM)

3.5

4.8

Figure 4.11: Absorption vs Log of probe concentration for A375 and SK-MEL-5 cells treated with
probe 1a.
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IC50 values were calculated as 3.5 µM and 4.8 µM respectively. These values are
relatively low, comparable to those of prodrugs activated by TrxR1, and indicate the
potential utility of diselenide probes in theranostics. 92 Melanoma cells have a high basal
protein level of TrxR1 and as a result may be reliant on TrxR1 activity to manage their
cellular stress responses. In the presence of 1a, TrxR1 may preferentially reduce this probe
instead of its intended substrate, Trx. This can result in a decline in Trx-mediated processes
such as DNA synthesis and ROS scavenging, resulting in cell death. Ongoing studies in
our labs are focused on investigating 1a and congeners as theranostic agents,
In conclusion, probe 1a enables the selective detection and imaging of TrxR1. This
can be useful in determining cellular redox status and disease detection. The proposed turnon mechanism of probe 1a was confirmed via LC-MS. In docking studies, the diselenide
probe had greater binding affinity to the TrxR1 active site compared to the disulfide
analogue. The binding affinity was confirmed by a favorable Km value (15.89 μM) for 1a
in comparison to previously reported probes for TrxR1 (vide supra).33, 43, 44, 47 Both probes
1a and 1b fluoresced in lung cancer cells, with a decline in fluorescence in cells pretreated
with DNCB, an inhibitor of TrxR1. However, 1a exhibited greater fluorescence than 1b at
DNCB concentrations < 20 μM. Diselenide- based probes offer a potential tool for the
detection of melanoma where TrxR is overexpressed.
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Chapter 5: Fluorescence-labelled ethaselen mimetic as a theranostic tool for cancer

Introduction
Based on the low IC50 values obtained with the diselenide probe 1a in cancer cells,
we aimed to synthesize a new series of selenium probes that are specifically tailored for
theranostic application. Selenium has been dubbed the "necessary poison" or "essential
toxin", since it can either be beneficial in cancer prevention or sometimes toxic, depending
on the form and amount of exposure.93 The RDA in adults is 55 μg whereas toxicity levels
start around 400 μg.94, 95 Many organic and inorganic Se compounds have been evaluated
for their efficacy and mechanism of cancer prevention which is mainly attributed to the
induction of apoptosis and increased sensitization to other therapeutics. The design of the
probes will mimic known antineoplastic Se compounds.
Tumor cell apoptosis can be triggered by selenoamino acids, Se-heterocylcles,
selenocyanates, diselenides, selenides and Se(IV) compounds through the activation or
deactivation of kinases, caspases and the p53 protein that regulates DNA repair and cell
death.96-99 Similar to probe 1a, other diselenides disturb the cell redox balance through
their reactions with selenoproteins and inhibition of mitogen-activated protein kinases
(MAPK), resulting in autophagy.100
In this study, we employ a selenium heterocycle designed to bind and inhibit TrxR1.
This is based on the known heterocylces which bind to the TrxR1 active site and inhibit
the enzyme, leading to reduced cancer cell growth (Figure 5.1).64, 101-104
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Figure 5.1. Structure of ethaselen, SeD3 and other selenadiazole molecules that inhibit TrxR or
sensitize cells to chemotherapy

The interaction of these compounds with thiols and selenoproteins leads to oxidative stress
through decreased cellular reductive capacity and increased ROS production. Since tumors
have elevated ROS levels, increasing the oxidative stress will result in further unfavorable
perturbations that lead to cell death.105 Ethaselen, for example, has a low IC50 of 7.5 µM in
Tca8113 tongue cancer cells. SeD3, on the other hand, has an EC50 (50 % inhibition of
TrxR) of 18.7 µM and an IC50 of 4.8 µM in HeLa cells. When TrxR1 is knocked out or has
reduced levels, the cytotoxicity of these compounds is reduced.106
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Figure 5.2. A. Structure of the TrxR1 inhibitor, ethaselen. B. Interaction of ethaselen with the
enzyme active site through a concerted attack by the Cys497 and Cys498 residues. Note, in the
wild type TrxR1, Cys498 is Sec498. C. Covalent interaction of the Se in ethaselen with Cys497
and Cys 498.Adapted with permission from64 Copyright © 2011 Elsevier Inc. All rights reserved.

Ethaselen is classified as an orally administered antineoplastic drug wihich is
currently in phase I clinical trials for its activity on TrxR1.64, 107-110 It is the first Se-based
inhibitor of TrxR1 that is proven to be highly specifc through binding onto the C- terminal
selenocysteine-cysteine active site.64 The inhibition of TrxR1 by ethaselen is monitered by
the DTNB assay. The Se-N bond is susceptible to reduction by TrxR1 and based on
molecular dynamic simulations, ethaselen is conveniently attacked first by the more potent
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Sec, and then the Cys residue reduces the second Se-N (Figure 5.2B, C). This leads to a
dose dependent increase in ROS production and cytotoxicity.111

Design and synthesis of theranostic probes
The following probes were designed and synthesized with fluorophores conjugated
to the Se-heterocycle. When reduced by TrxR1, the Se-N bond is broken and this results in
a change in the photochemical properties of the probes. Hence, a change in the fluorescence
is expected and this will allow simultaneous TrxR1 detection and inhibition.

Figure 5.3. Structure of probes synthesized for theranostic targeting of TrxR
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The electron-withdrawing Se-heterocycle was shown to quench an anthraquinone
analogue, and this is decaged into the diamine form after reacting with biothiols (Figure
5.4).

Figure 5.4. An anthraquinone analogue that fluoresces when uncaged by biothiols. Adapted with
permission from112 Copyright © 2018 Elsevier Inc. All rights reserved.
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Synthesis
Synthesis of benzo[c][1,2,5]selenadiazole-5-carboxylic acid

3,4-diaminobenzoic acid, (1.00 g, 6.57 mmol) and selenium dioxide (1.09 g, 9.86
mmol) were mixed, and 1 mL of water was added. The mixture was stirred for 2 h and a
brownish-yellow solid was obtained. The product was washed with water (3 x 25 mL) and
filtered to dryness before being recrystallized in dioxane overnight. A pure, tan product 14
(benzo[c][1,2,5]selenadiazole-5-carboxylic acid) was obtained at 48 % yield. ESI-MS
(m/z) calc for C11H11O2 [M + H]+: 228.9516, found: 228.9654. 1H NMR (400 MHz,
DMSO-d6) δ 13.5 (s, 1H), 8.5 (s, 1H), 7.98 (t, 2H).

13

C NMR (101 MHz, DMSO-d6) δ

167.31, 161.15, 159.60, 131.63, 128.29, 125.84, 123.70.

Synthesis of benzo[c][1,2,5]selenadiazole-5-carbonyl chloride

0.5 g (2.20 mmol) of 14 was weighed out into a round bottom flask. 20 mL of
thionyl chloride was added and the mixture was refluxed for 3 h. The thionyl chloride was
evaporated off. Toluene (2 x 40 mL) was used to remove excess thionyl chloride and a
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light-yellow powder was obtained. IR spectra was run to compare 14 and 15. The
disappearance of the -OH peak was noted, coupled with the appearance of the C-Cl peak.
The product was used without further purification.
Synthesis of 2-(8-hydroxy-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinoline-9carbonyl)benzoic acid

Phthalic anhydride (783 mg, 5.28 mmol) and 8-hydroxyjulolidine (1.0 g, 5.28
mmol) were dissolved in 25 mL of toluene. The mixture was refluxed for 24 h, then the
solvent was removed under vacuum. The compound was purified by flash chromatography
on silica gel using DCM:MeOH 95:5 for elution.726 mg (41 % yield) of a pale yellow solid
16 was obtained. ESI-MS (m/z) calc for C20H19NO4 [M + H]+: 338.1392, found: 338.1298.
1

H NMR (400 MHz, DMSO-d6) δ 12.94 (s, 1H), 7.95 – 7.93 (m, 1H), 7.69 (dt, J = 7.5, 3.8

Hz, 1H), 7.66 (dt, J = 7.6, 3.8 Hz, 1H), 7.59 (d, J = 6.5 Hz, 1H), 6.39 (s, 1H), 4.17 (s, 1H)
3.24 (dd, J = 11.6, 7.0 Hz, 4H), 2.78 (t, J = 6.4 Hz, 2H), 2.57 (t, J = 6.1 Hz, 2H), 1.88 –
1.82 (m, 2H), 1.79 – 1.73 (m, 2H). 13C NMR (101 MHz, DMSO) δ 198.36, 167.46, 160.24,
149.27, 140.62, 132.31, 130.13, 129.69, 128.20, 112.92, 108.80, 105.08, 49.86, 49.41,
49.07, 27.13, 21.56, 20.56, 20.04.
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Synthesis of 7-aminonaphthalen-2-ol

2,7-dihydroxynaphthalene (5 g, 31.22 mmol), formamide (1.55 g, 34.41 mmol) and
sodium sulfite (8.26 g, 65.54 mmol) were suspended in 50 mL of DI water and refluxed
for 12 h. The solid formed was collected by filtration and washed with water (100 mL).
The product was dissolved in 100 mL of diethyl ether and washed with 100 mL of 6 N HCl
in a separatory funnel. The aqueous layer was collected and pH was raised to 13 using
NaOH. Liquid-liquid extraction was repeated with 100 ml diethyl ether. The aqueous layer
was then neutralized to pH 7 with 2 N HCl and extracted with ethyl acetate (3 x 100 mL).
The organic extracts were combined, dried over Na2SO4 and the solvent evaporated under
vacuum. A pure product 17 was obtained in 77 % yield. ESI-MS (m/z) calc for C10H9NO
[M + H]+: 160.0762, found: 160.0782. 1H NMR (400 MHz, DMSO-d6) δ 9.61 (s, 1H),
7.45 (d, J = 8.8 Hz, 1H), 7.43 (d, J = 8.8 Hz, 1H), 6.74 (s, 1H), 6.69 (dd, J = 8.9, 2.1 Hz,
1H), 6.67 (dd, J = 9.0, 2.2 Hz, 1H), 6.59 (d, J = 2.1 Hz, 1H), 5.20 (s, 2H). 13C NMR (101
MHz, DMSO-d6) δ 156.03, 147.22, 137.24, 129.36, 128.78, 120.56, 115.62, 113.97,
105.07, 104.57
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Synthesis of 11-amino-2,3,6,7-tetrahydro-1H,3'H,5H-spiro[benzo[5,6]chromeno[2,3f]pyrido[3,2,1-ij]quinoline-9,1'-isobenzofuran]-3'-one

16 (100 mg, 0.296 mmol) and 17 (71 mg, 0.444 mmol) were dissolved in 1.5 mL
of methanesulfonic acid and 1.5 mL of TFA. The mixture was stirred at 80°C for 24 h, then
cooled down to room temperature and poured into 50 mL of DI water before being
neutralized by portion-wise addition of NaHCO3. The purple precipitate obtained was
filtered and washed with DI water and air-dried. The target compound was isolated by flash
column chromatography on silica gel using CH2Cl2:MeOH 90:10,80:20, 38 % yield. ESIMS (m/z) calc for C30H25N2O3 [M + H]+: 461.0865, found: 461.0724. 1H NMR (400 MHz,
DMSO-d6) δ 8.08 (d, 1H), 7.75 -7.77 (d, 1H) 7.69 – 7.77 (m, 2H), 7.55 (d, J = 8.6 Hz, 1H),
7.08 (d, J = 8.9 Hz, 1H), 6.71 (d, J = 8.8Hz, 1H), 5.90 (s, 1H), 5.83 (s, 1H) 5.20 (s, 1H),
3.14 (m, 2H), 3.09 (m, 3H), 2.88 (m, 2H), 2.40 (m, 1H), 1.94 (m, 1H), 1.75 (m, 1H) 13C
NMR (101 MHz, DMSO-d6) δ 206.96, 169.90, 155.12, 151.33, 148.14, 145.66, 144.05,
135.88, 133.54, 132.71, 130.76, 129.91, 127.01, 125.75, 123.81, 118.15, 116.07,106.54,
106.25, 103.73, 49.49, 31.17, 27.41, 21.73, 21.08,
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Synthesis of N-(3'-oxo-2,3,6,7-tetrahydro-1H,3'H,5H-spiro[benzo[5,6]chromeno[2,3f]pyrido[3,2,1-ij]quinoline-9,1'-isobenzofuran]-11-yl)benzo[c][1,2,5]selenadiazole-5carboxamide

18 (500 mg, 1.09 mmol) and 15 (533 mg, 2.17 mmol) were added to a R.B.F and
purged with N2. 20 mL of anhydrous DCM and triethylamine (0.3 mL) was added dropwise.
The reaction was stirred at room temperature for 36 h. The solvent was removed by vacuum
and the product detected via LC-MS (with starting material present). Pure fractions of the
compound were obtained through either reverse phase HPLC (Water:Acetonitrile gradient
elution) or silica gel chromatography (CHCl3, 10 % Formic acid and then CHCl3:MeOH
95:5). 11 was obtained in 41 % yield. ESI-MS (m/z) calc for C37H27N4O4Se [M + H]+:
671.1198, found: 671.2120. 1H NMR (400 MHz, DMSO-d6) δ 10.45 (s, 1H), 8.42 (s, 1H),
8.16 (d, J= 8.7 Hz, 1H), 8.03 (s, 2H), 7.92 (m, 3H), 7.63 (m, 2H), 7.49 (d, J = 8.8 Hz, 2H)
7.09 (s, 1H), 5.94, (s, 1H), 3.17 (m, 4H), 2.93 (t, 1H), 2.43 (m, 2H), 1.97 (s, 1H), 1.77 (s,
1H) 13C NMR (101 MHz, DMSO-d6) δ 170.30, 168.85, 152.55, 152.38, 149.05, 135.22,
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129.76, 128.54, 126.80, 124.33, 124.06, 108.16, 105.15, 96.92, 84.88, 59.72, 43.75, 20.72,
14.05, 12.30.

Synthesis of N-(1-methoxy-3'-oxo-3'H-spiro[benzo[c]xanthene-7,1'-isobenzofuran]10-yl)benzo[c][1,2,5]selenadiazole-5-carboxamide

2 (150 mg, 0.38 mmol) and 15 (186 mg, 0.76 mmol) were added to a R.B.F and
purged with N2. 20 mL of anhydrous DCM was added and triethylamine (0.3 mL) was
added dropwise. The reaction was stirred at room temperature for 36 h. The solvent was
then removed by vacuum and the product detected via LC-MS (with starting material
present). Flash chromatography was carried out with DCM:MeOH 95:5. The product
coelluted with starting material and a second column was run with Hexane:Ethyl Acetate
3:1. The pure fraction 12 was eventually obtained by crystallization in methanol, 25 %
yield. ESI-MS (m/z) calc for C32H19N3O5Se [M + H]+: 606.0568, found: 606.1450. 1H
NMR (400 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.15 (s, 1H), 8.10 (m, 2H), 8.00 (s, 1H), 7.79
(m, 2H) , 7.76, (m, 3H) 7.50 (d, J = 8.8 Hz, 1H), 7.37 (d, J = 8.7 Hz, 1H), 7.22 (d, J =
8.8HZ, 1H), 6.78 (d, J = 8.6 Hz, 1H), 4.10 (s, 3H), 3.34 (s, 3H)

13

C NMR (101 MHz,

DMSO-d6) δ 206.98, 169.92, 155.14, 151.35, 148.16, 145.67, 144.07, 135.89, 133.55,
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132.72, 130.77, 129.92, 127.02, 125.76, 123.82, 123.56, 118.16, 116.08, 112.97, 106.55,
106.26, 105.69, 103.74, 84.97, 49.94, 49.04, 31.17, 27.41, 21.73, 21.08, 20.97.

Synthesis of 2-(2-hydroxy-4-methoxybenzoyl)benzoic acid

Phthalic anhydride (0.94 g; 7.57 mmol) and anhydrous AlCl3 were dissolved in
anhydrous DCM (40 mL). The mixture was stirred at rt for 5 min. 3-methoxy phenol (1.00
g; 8.06 mmol) was then added dropwise over 30 minutes and the reaction mixture was
stirred at rt for 20 h. The mixture was poured into ice water (100 ml) and conc. HCl (25
mL), extracted with DCM (3 × 100 mL) and dried over sodium sulfate. The solvent was
then evaporated. Compound 19 was obtained by silica gel chromatography: Hexane:Ethyl
acetate 2:1, 1:1, 1:3, at 60 % yield. ESI-MS (m/z) calc for C15H12O5 [M + H]+: 273.0763,
found: 273.0805. 1H NMR (400 MHz, DMSO-d6) δ 13.25 (s, 1H), 12.26 (s, 1H), 8.01 (s,
1H), 7.73 (m, 1H), 7.64 (m, 1H), 7.46 (s, 1H), 6.99 (d, J = 8.5 Hz, 1H), 6.56, (s, 1H), 6.43
(s, 1H), 3.34 (t, 3H) 13C NMR (101 MHz, DMSO-d6) δ 201.27, 167.12, 166.18, 164.13,
140.36, 134.59, 132.42, 129.85, 127.79, 114.65, 107.86, 101.44, 56.26.
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Synthesis of 2-amino-9-methoxy-3'H-spiro[benzo[a]xanthene-12,1'-isobenzofuran]3'-one

Compound 19 (590 mg, 2.17 mmol) and compond 17 (517 mg, 3.25 mmol) were dissolved
in 2 ml of MSA and then 2 ml of TFA. The mixture was then stirred at 80°C for 16 h, after
which it was cooled down to room temperature and poured into 50 ml of DI water. The
mixture was neutralized to pH 7 using NaHCO3. The precipitate formed was filtered under
vacuum, washed with 25 ml of DI water and air dried. The product was purified via column
chromatography with CH2Cl2 : MeOH 9:1 as the eluent, to obtain a pure compound 20,
82 % yield. ESI-MS (m/z) calc for C25H18NO4 [M + H]+: 396.1236, found: 396.1281. 1H
NMR 8.00 (d, J=8.6 Hz, 1H), 7.77 (dd, 2H) 7.27 (s, 1H) 6.93 (s, 1H) 6.72 (m, 4H) 3.72 (s,
6H), 13C NMR (101 MHz, DMSO-d6) δ 169.09, 161.53, 152.95, 152.33, 136.19, 130.70,
129.50, 126.35, 125.21, 124.41, 112.43, 111.34, 101.25, 82.21, 56.13.

87

Synthesis of N-(9-methoxy-3'-oxo-3'H-spiro[benzo[a]xanthene-12,1'-isobenzofuran]2-yl)benzo[c][1,2,5]selenadiazole-5-carboxamide

20 (460 mg, 1.16 mmol) and 15 (1.14g mg, 4.63 mmol) were added to a R.B.F and purged
with N2. 40 mL of anhydrous DCM was added, and triethylamine (1 mL) was added
dropwise. The reaction was stirred at room temperature for 36 h. The solvent was then
removed by vacuum. The pure compound was obtained by suspending in MeOH, followed
by vacuum filtration. A yellowish-green solid 13 was obtained ESI-MS (m/z) calc for
C32H20N3O5Se [M + H]+: 606.0568, found: 606.0598. 1H NMR (400 MHz, DMSO-d6) δ
8.49 (s, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.01 (d, J = 8.7 Hz, 1H), 6.53 (s, 1H), 3.01 (s, 3H) ,
2.02 (m, 4H), 1.97 (m, 4H)

13

C NMR (101 MHz, DMSO-d6) δ 172.32, 169.89, 154.23,

149.97, 137.02, 129.89, 129.23, 126.57, 122.21, 109.91, 107.12, 98.76,59.98, 43.32, 20.02,
19.78, 12.38, 11.39.
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Docking simulations

Molecular docking was carried out using Autodock Vina and visualized with UCSF
Chimera, in an analogous way to that done in Chapter 2.

Figure 5.5. Docking of 11 onto the TrxR active site showing the interaction of Sec with the
selenadiazole ring.

89

Table 5.1. Binding affinity of probes onto the TrxR enzyme active site
ΔGbind
ΔGbind
Probe

Structure

Probe

Structure

(kcal/

(kcal/mol)
mol)

11

-13.9

13

-12.0

12

-12.0
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Probe Reactivity
20 µM of each probe was dissolved in 0.6 % DMSO and 0.2 % NP-40 in PBS, pH 7.4 and
absorption and fluorescence data was collected. All three probes showed maximum
absorption at 345 nm with no visible fluorescence (Figure 5.4).
30
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Figure 5.4. Absorption spectra of probes 11, 12 and 13. The spectra did not change in the presence
of reductive species and ROS.

The reactivity of the probes was tested against various oxidative and reductive species and
the UV-Vis and fluorescence data collected. Briefly, 20 µM of each probe was mixed with
1-10 equiv of the following in PBS buffer, pH 7.4:
Reductive species: GSH, Cys, Hcy, H2S, Sec, DTT and TCEP
Reactive oxygen species: H2O2, ClO-, tButOOH and OH•.
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The mixtures were incubated at 37 ⁰C and UV-Vis and fluorescence data collected at 15
min intervals over 2 h. There was no observable change in the spectra, suggesting no
reactivity with any other reagents.

Treatment of HEK-239 and ES-2 cells with probe 11-loaded polymeric nanoparticles
We aimed to measure fluorescence of ES-2 ovarian cancer cells and HEK-239
embryonic cells treated with 11. The probe was encapsulated into nanoparticles to enhance
its absorption into cells. To produce the PEG-PCL working solution (41 mg/mL, 2.73 mM),
84 g of PEG-PCL polymer was mixed with 2 mL acetone and sonicated for 2 min. For
encapsulation of probes, 488 µL of PEG-PCL solution (5K-10K, 2.73 mM in acetone) and
40 µL of probe original stock (10 µM in acetone) were mixed in acetone to a total volume
of 2 mL. Under constant stirring, saline (2 mL) was added to the vial. Acetone was
evaporated using a rotary evaporator with a water bath temperature of 40 °C and a rotation
speed of 100 rpm. The evaporation followed a three-segment cycle: first at 400 mbar for 7
min, then 320 mbar for 7 min, and finally 200 mbar for 6 min. The final volume of the
nanoparticle solution was adjusted to 2 mL with saline and centrifuged at 10,062 RCF for
5 min. The supernatant was filtered through a 0.2 µm filter (cellulose acetate, VWR
International, Radnor, PA) to collect dispersed nanoparticles with desired probe loading
amounts. The hydrodynamic diameter (Polydispersity index) and surface charge (ζpotential) of nanoparticles were characterized with Malvern Zetasizer Nano ZS instrument
(Malvern, Worcestershire, UK).
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The cells were treated with different concentrations of 11 and incubated at 37°C.
Fluorescence measurements were then taken after 0 and 30 min at λexc = 530 nm, λem = 645
nm. There was virtually no fluorescence at the start of the experiment and this increased
gradually with time.

2.6
2.4

ES-2 cells
HEK 293 cells

2.2
2.0
1.8
1.6

I 1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
20µM 11 10µM 11 5µM 11

20µM 11 10µM 11 5µM 11

[Probe]
Figure 5.5. Fluorescence response of 11 in ES-2 ovarian cancer cells and HEK 239 embryonic
kidney cells after 30 min incubation (λexc = 530 nm, λem = 645 nm).

ES-2 ovarian cancer cells gave greater fluorescence in comparison to the HEK 293
embryonic cells. This is congruent with our hypothesis that the probes would be more
active in cancerous cells where TrxR is overexpressed.
We envision that the probe covalently binds to the enzyme active site through a Se-Se bond.
This uncages the -NH2 group, resulting in a change in the photochemical properties of the
probe (Figure 5.6).
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Figure 5.6. Reaction of 11 with TrxR which leads to uncaging of the selenadiazole ring, resulting
in fluorescence

Cytotoxicity Assay
The in vitro cell viability studies were performed using luminescent Cell Titer-Glo
assay (Promega Corp., Madison, WI). Experiments were carried out with human HEK 293
cells after 24 h inoculation of probes in growth media (DMEM, 10% FBS, 1% penicillin,
streptomycin). Each probe was tested at 100.00 µM, 50.00 µM, 25 µM, 12.50 µM, 6.25
µM, 3.13 µM, 1.56 µM, 0.78 µM, 0.39 µM, 0.20 µM, 0.10 µM, and blank (biological
replicate n = 8, technical replicate n = 3). The percent cell viability in the CellTiter-Glo®
assay was determined based on the luminescent signal, which is proportional to the amount
of ATP produced by living cells. No interference of the probes with the CellTiter-Glo
assay reagent was observed. The luminescent signal was normalized to total protein
amounts that were determined using a Pierce BCA protein assay kit (Thermo scientific).
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Figure 5.7. % cell viability versus concentration of 11. IC50 was calculated as 1.503 µM.

11 had a low IC50 value of 1.503 µM, comparable to that of other selenadiazole compounds
that target TrxR. We envision that the probe will covalently bind to the active site through
a covalent Se-Se bond. This inhibition of TrxR will result in an increase in ROS production
which ultimately leads to cell death.
The data currently available of the selenadiazole based probes shows potential in
the theranostic application of these probes. There is still room to collect more data
regarding the selectivity of the probes to TrxR and also comparing the cytotoxicity in
different cell lines.
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Chapter 6: Conclusion and future work
The use of fluorescent molecules allows monitoring of biological processes in real
time and with high resolution. Focused designs are also applied in the selective and rapid
detection of biological analytes. In this work, we focused on the detection of thioredoxin
reductase, an enzyme that has sparked interest as a target for the detection of cancer as well
as therapy.
We designed and applied a diselenide based probe, 1a, that had a turn-on response
in the presence of TrxR. The probe did not give a significant response in the presence of
other reducing biological analytes, showing that it was selective for the enzyme. Molecular
docking and kinetic studies proved that diselenide probes had greater binding affinity and
a faster turn-on response in comparison to disulfide analogues. This was examplified with
probes in literature and also the disulfide anlogue to 1a, probe 1b. The diselenide probes
therefore address the need for the fast and specific detection of TrxR. 1a also exhibits
cytotoxicity torwards melanoma cells.
The selenadiazole based group of probes also show promise in the detection of
TrxR. Probes 11, 12 and 13 are robust, as they show no fluorescence change in the presence
of reductive species such as GSH, Cys and Hcy. Fluorescence response was however
recorded in human ovarian cancer cells. Human embryonic kidney cells also gave
fluorescence, but at a lower intensity in comparison to cancerous cells. These probes also
exhibit low IC50 values towards cells due to the inhibiton of TrxR.
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There is still need to design more probes that can target TrxR for theranostic
purposes. One way this can be done is through the synthesis of fluorophores that have the
selenadiazole ring directly attached to the xanthene scafffold. This eliminates the need for
a carbamate linker and will likely have very distinct fluorescence change. Selectivity and
cytotoxicty assays will also be carried out between cells that overexpress TrxR and those
that have the TrxR gene knocked out.
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Appendix A: Supporting information for Chapter 2

Figure A1. 1H NMR spectrum of compound 7.
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Figure A2. 13C NMR spectrum of compound 7.
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Figure A3. ESI positive mode spectrum of compound 7.
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Figure A4. 1H NMR spectrum of compound 3.

105

Figure A5. 13C NMR spectrum of compound 3.
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Figure A6. ESI positive mode spectrum of compound 3.
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Figure A7. 1H NMR spectrum of compound 5.
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Figure A8. 13C NMR spectrum of compound 5.
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Figure A9. ESI positive mode spectrum of compound 5.
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Figure A10. 1H NMR spectrum of compound 2.

111

Figure A11: 13C NMR spectrum of compound 2.
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Figure A12: ESI positive mode spectrum of compound 3.
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Figure A13: HPLC chromatogram of purified 1a
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Figure A14: ESI positive mode spectrum of compound 1a.
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Figure A15: 1H NMR spectrum of compound 1a.
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Figure A16: HPLC chromatogram of purified 1b.
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Figure A17: ESI positive mode spectrum of compound 1b.

118

Figure A18: 1H NMR spectrum of compound 1b.
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Figure A19: HPLC chromatogram of purified 1c.

Figure A20: ESI positive mode spectrum of compound 1c.

120

Appendix B: Supporting information for Chapter 3

Figure A21. ESI-MS positive mode spectrum for compound 14.

Figure A22. 1H NMR spectrum for compound 14.
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Figure A23. 13C NMR spectrum for compound 14.

Figure A24. IR spectra showing the conversion of 14 (red) to 15 (blue).
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Figure A25. ESI-MS positive mode spectrum for compound 16.

Figure A26. 1H NMR spectrum for compound 16.
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Figure A27. 13C NMR spectrum for compound 16.

Figure A28. ESI-MS spectrum for compound 17.
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Figure A29. 1H NMR spectrum for compound 17.

Figure A30. 13C NMR spectrum for compound 17.
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Figure A31. ESI-MS spectrum for compound 18.

Figure A32. 1H NMR spectrum for compound 18.
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Figure A33. 13C NMR spectrum for compound 18.

Figure A34. ESI-MS spectrum for compound 19.
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Figure A35. 1H NMR spectrum of 19.

Figure A36. 13C NMR spectrum of 19.
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Figure A37. ESI-MS spectrum for compound 20.
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Figure A38. 1H NMR spectrum for compound 20.

Figure A39. 13C NMR spectrum for compound 20.
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Figure A40. HPLC chromatogram of purified compound 11.

Figure A41. ESI-MS spectrum for compound 11.
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Figure A42. 1H NMR spectrum for compound 11.

Figure A43. 13C NMR spectrum for compound 11.
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Figure A44. HPLC chromatogram of purified compound 12.

Figure A45. ESI-MS spectrum for compound 12.
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Figure A46. 1H NMR spectrum for compound 12.

Figure A47. 13C NMR spectrum for compound 12.
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Figure A48. 1H NMR spectrum for compound 13.

Figure A49. 13C NMR spectrum for compound 13.
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Figure A50. HPLC chromatogram of purified compound 13.

Figure A51. ESI-MS spectrum for compound 13.
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